A LC/MS/MS micro-method for human plasma quantification of vemurafenib: Application to treated melanoma patients

Journal of Pharmaceutical and Biomedical Analysis

Volumn 97, Issue , 2014, Pages 29-32

  Alvarez, Jean Claude ^a   Funck Brentano, Elisa ^b   Abe, Emuri ^a   Etting, Isabelle ^a   Saiag, Philippe ^b   Knapp, Adeline ^a  

^a Laboratoire de Pharmacologie Toxicologie Centre Hospitalier Universitaire Raymond Poincaré AP HP   (France)

^b Service de dermatologie Centre Hospitalier Universitaire Ambroise Paré AP HP   (France)

Author keywords

LC MS MS; Melanoma; Pharmacokinetic; Plasma; Vemurafenib

Indexed keywords

ACETONITRILE; CARBON 13; ION; PROTEIN; VEMURAFENIB; WATER; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MIDDLE AGED; PRECIPITATION; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY; BLOOD; DOSE RESPONSE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INDOLES; LIMIT OF DETECTION; MALE; MELANOMA; MIDDLE AGED; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 84899879031     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.04.014     Document Type: Article

References (10)

1. Davies H., Bignell G.R., Cox C., Stephensen P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
2. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
3. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., Hogg D., Lorigan P., Lebbe C., Jouary T., Schadendorf D., Ribas A., O'Day S.J., Sosman J.A., Kirkwood J.M., Eggermont A.M., Dreno B., Nolop K., Li J., Nelson B., Hou J., Lee R.J., Flaherty K.T., McArthur G.A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
4. Fischer R., Larkin J. Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manage. Res. 2012, 4:243-252.
5. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., Lassalle R., Marit G., Reiffers J., Begaud B., Moore N., Molimard M., Mahon F.X. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
6. Cortes J.E., Egorin M.J., Guilhot F., Molimard M., Mahon F.X. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 2009, 23:1537.
7. Zheng Y., Thomas-Schoemann A., Sakji L., Boudou-Rouquette P., Dupin N., Mortier L., Vidal M., Goldwasser F., Blanchet B. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. J. Chromatogr. B 2013, 928:93-97.
8. Ravnan M.C., Matalka M.S. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin. Ther. 2012, 7:1474-1486.
9. Sparidans R.W., Durmus S., Schinkel A.H., Schellens J.H.M., Beijnen J.H. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. J. Chromatogr. B 2012, 889:144-147.
10. Nijenhuis C.M., Rosing H., Schellens J.H.M., Beijnen J.H. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma. J. Pharm. Biomed. Anal. 2014, 88:630-635.